Pharmacokinetics and disposition of recombinant human osteoprotegerin (rhOPG) after intravenous administration in female fischer rats

References

• Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan, CR. 2001. The effect of a single dose of osteoprotegerin in postmenopausal women. Journal of Bone and Mineral Research 16:348–360.
   PubMed Web of Science ®Google Scholar
• Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, et al.. 2003. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97:887–892.
   PubMed Web of Science ®Google Scholar
• Capparelli C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan, CR. 2000. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Research 60:783–787.
   PubMed Web of Science ®Google Scholar
• Capparelli C, Morony S, Warmington K, Adamu S, Lacey D, Dunstan CR, Stouch B, Martin S, Kostenuik, PJ. 2003. Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats. Journal of Bone and Mineral Research 18:852–858.
   PubMed Web of Science ®Google Scholar
• Cheng Z, Chen J, Quinn TP, Jurisson, SS. 2004. Radioiodination of rhenium cyclized alpha-melanocyte-stimulating hormone resulting in enhanced radioactivity localization and retention in melanoma. Cancer Research 64:1411–1418.
   PubMedGoogle Scholar
• Colin S, Jeanny JC, Mascarelli F, Vienet R, Al-Mahmood S, Courtois Y, Labarre J.. 1999. In vivo involvement of heparan sulfate proteoglycan in the bioavailability, internalization, and catabolism of exogenous basic fibroblast growth factor. Molecular Pharmacology 55:74–82.
   Google Scholar
• Hepburn TW, Hart TK, Horton VL, Sellers TS, Tobia LP, Urbanski JJ, Shi W, Davis, CB. 2001. Pharmacokinetics and tissue distribution of SB-251353, a novel human CXC chemokine, after intravenous administration to mice. Journal of Pharmacology and Experimental Therapeutics 298:886–893.
   Google Scholar
• Honore P, Luger NM, Sabino MA, Schwei MJ, Rogers SD, Mach DB, O’Keefe PF, Ramnaraine ML, Clohisy DR, Mantyh, PW. 2000. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nature Medicine 6:521–528.
   PubMed Web of Science ®Google Scholar
• Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I., et al. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proceedings of the National Academy of Sciences, USA 96:3540–3545.
   PubMed Web of Science ®Google Scholar
• Ji ZS, Sanan DA, Mahley, RW. 1995. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. Journal of Lipid Research 36:583–592.
   PubMed Web of Science ®Google Scholar
• Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.. 1997. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Journal of Pharmacology and Experimental Therapeutics 283:520–527.
   PubMedGoogle Scholar
• Kostenuik PJ, Capparelli C, Morony S, Adamu S, Shimamoto G, Shen V, Lacey DL, Dunstan, CR. 2001. OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology 142:4295–4304.
   PubMed Web of Science ®Google Scholar
• Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, et al. 1998. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176.
   PubMed Web of Science ®Google Scholar
• Mochizuki S, Fujise N, Higashio K, Tsuda E.. 2002. Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats. Journal of Bone and Mineral Metabolism 20:14–20.
   Web of Science ®Google Scholar
• Morony S, Capparelli C, Lee R, Shimamoto G, Boone T, Lacey DL, Dunstan, CR. 1999. A chimeric form of osteoprotegerin inhibits hypercalcemia and bone resorption induced by IL-1beta, TNF-alpha, PTH, PTHrP, and 1, 25(OH)2D3. Journal of Bone and Mineral Research 14:1478–1485.
   PubMed Web of Science ®Google Scholar
• Mosheimer BA, Kaneider NC, Feistritzer C, Djanani AM, Sturn DH, Patsch JR, Wiedermann, CJ. 2005. Syndecan-1 is involved in osteoprotegerin-induced chemotaxis in human peripheral blood monocytes. Journal of Clinical Endocrinology and Metabolism 90:2964–2971.
   PubMedGoogle Scholar
• Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, et al.. 1997. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319.
   PubMed Web of Science ®Google Scholar
• Standal T, Seidel C, Hjertner O, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A.. 2002. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood 100:3002–3007.
   PubMed Web of Science ®Google Scholar
• Takakura Y, Fujita T, Hashida M, Maeda H, Sezaki H.. 1989. Control of pharmaceutical properties of soybean trypsin inhibitor by conjugation with dextran. II: Biopharmaceutical and pharmacological properties. Journal of Pharmaceutical Sciences 78:219–222.
   PubMed Web of Science ®Google Scholar
• Théoleyre S, Kwan Tat S, Vusio P, Blanchard F, Gallagher J, Ricard-Blum S, Fortun Y, Padrines M, Rédini F, Heymann D.. 2006. Characterization of osteoprotegerin binding to glycosaminoglycans by surface plasmon resonance: role in the interactions with receptor activator of nuclear factor kappaB ligand (RANKL) and RANK. Biochemical and Biophysical Research Communications 347:460–467.
   PubMedGoogle Scholar
• Tomoyasu A, Goto M, Fujise N, Mochizuki S, Yasuda H, Morinaga T, Tsuda E, Higashio K.. 1998. Characterization of monomeric and homodimeric forms of osteoclastogenesis inhibitory factor. Biochemical and Biophysical Research Communications 245:382–387.
   PubMed Web of Science ®Google Scholar
• Tsuda E, Goto M, Mochizuki S, Yano K, Kobayashi F, Morinaga T, Higashio K.. 1997. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochemical and Biophysical Research Communications 234:137–142.
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Kinosaki M, Goto M, Kobayashi F, Tsuda E, Morinaga T, Higashio K.. 1998. Characterization of structural domains of human osteoclastogenesis inhibitory factor. Journal of Biological Chemistry 273:5117–5123.
   PubMed Web of Science ®Google Scholar
• Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K, Yamada Y.. 1999. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 14:518–527.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, Sato Y, Goto M, Yamaguchi K, Kuriyama M, et al. 1998b. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139:1329–1337.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, et al. 1998a. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proceedings of the National Academy of Sciences USA 95:3597–3602.
   PubMed Web of Science ®Google Scholar
• Zierhut ML, Gastonguay MR, Martin SW, Vicini P, Bekker PJ, Holloway D, Leese PT, Peterson, MC. 2008. Population PK-PD model for Fc-osteoprotegerin in healthy postmenopausal women. Journal of Pharmacokinetics and Pharmacodynamics 35:379–399.
   Google Scholar
• Zioncheck TF, Richardson L, DeGuzman GG, Modi NB, Hansen SE, Godowski, PJ. 1994. The pharmacokinetics, tissue localization, and metabolic processing of recombinant human hepatocyte growth factor after intravenous administration in rats. Endocrinology 134:1879–1887.
   PubMed Web of Science ®Google Scholar